Exocrine pancreatic insufficiency (EPI) happens when your pancreas can no longer produce enough digestive enzymes to properly break down food. The most common cause is chronic pancreatitis, but EPI can also develop after surgery, from genetic conditions like cystic fibrosis, and even as a complication of diabetes or celiac disease. The underlying trigger varies widely, but the result is the same: fat, protein, and nutrients pass through your gut undigested, leading to oily stools, weight loss, bloating, and nutritional deficiencies.
Chronic Pancreatitis
Chronic pancreatitis is the leading cause of EPI in adults. Years of inflammation gradually destroy the enzyme-producing cells of the pancreas, replacing them with scar tissue. The damage is cumulative, which is why EPI often doesn’t appear right away. At the time of a chronic pancreatitis diagnosis, only 6 to 22% of patients have EPI. After five years, that number rises to about 28%. By roughly 12 years after diagnosis, half of all chronic pancreatitis patients have developed it.
Heavy alcohol use is the most common driver of chronic pancreatitis in Western countries, but gallstones, genetic mutations, and repeated episodes of acute pancreatitis can all lead to the same slow destruction. The pancreas has a large reserve capacity, so symptoms of EPI typically don’t surface until about 90% of enzyme output is lost. That’s why the condition can simmer for years before it becomes obvious.
Cystic Fibrosis
Cystic fibrosis (CF) is the most common genetic cause of EPI, and it starts early. The disease stems from a defect in a protein that controls the movement of chloride and bicarbonate ions across cell membranes. In a healthy pancreas, ductal cells secrete an alkaline fluid rich in bicarbonate that washes digestive enzymes out of the pancreatic ducts and into the small intestine. It also neutralizes stomach acid as food enters the gut.
When this protein doesn’t work correctly, the fluid becomes thick and protein-rich instead of thin and watery. That viscous secretion clogs the ducts with mucoprotein plugs, trapping enzymes inside the pancreas. Over time, this causes inflammation, calcification, cyst formation, and eventually widespread scarring that destroys the organ’s ability to produce enzymes at all. Most people with CF develop EPI in infancy or early childhood, and roughly 85% require enzyme replacement therapy for life.
Pancreatic and Gastrointestinal Surgery
Any surgery that removes part of the pancreas or rearranges the upper digestive tract can trigger EPI. The Whipple procedure, commonly performed for pancreatic head tumors, removes the head of the pancreas along with part of the small intestine and bile duct. This directly reduces enzyme output and disrupts the normal mixing of enzymes with food.
Stomach surgery causes EPI through a less obvious route. After a partial or total gastrectomy, food moves into the small intestine faster than normal, bypassing the signals that tell the pancreas to start secreting. Published incidence rates for EPI after gastric surgery range from 26% to 100%, depending on the type of procedure and how it’s measured. One study of 27 patients found a 33% incidence using stool testing, while other researchers have reported rates of 47 to 70% after different types of stomach reconstruction. Total gastrectomy tends to carry the highest risk, though one study found no statistically significant difference between total and subtotal procedures.
Autoimmune Pancreatitis
In autoimmune pancreatitis, the immune system attacks the pancreas directly, causing inflammation and swelling that can mimic pancreatic cancer on imaging. There are two types: one that affects multiple organs and is associated with elevated blood antibody levels, and one that targets only the pancreas and is often linked to inflammatory bowel disease.
Pooled data across studies shows that about 45% of patients have exocrine insufficiency at the time of diagnosis. After treatment with immunosuppressive therapy, the prevalence drops to around 36%, meaning some pancreatic function can recover once the inflammation is controlled. Still, more than a third of patients continue to need enzyme support even after treatment.
Diabetes
The connection between diabetes and EPI is underappreciated. In type 1 diabetes, the immune system destroys the insulin-producing cells clustered in small islands throughout the pancreas. These islands sit right next to the enzyme-producing cells, and the local blood supply that normally nourishes both gets disrupted. Insulin itself also appears to have a direct role in supporting enzyme-producing tissue, so its absence can starve those cells of a growth signal they depend on.
Prevalence estimates for EPI in type 1 diabetes range from 14% to 77.5%, with a median around 33%. That wide range reflects differences in how studies define and test for EPI, but even the conservative end is striking. Many of these patients have symptoms that overlap with common diabetes complaints (bloating, irregular bowel habits, difficulty maintaining weight), so EPI often goes unrecognized.
Celiac Disease
Celiac disease damages the lining of the small intestine, and that damage has downstream effects on the pancreas. Normally, when food enters the upper intestine, specialized cells in the gut wall release hormones that signal the pancreas to secrete enzymes and bicarbonate. In celiac disease, the intestinal lining is flattened and inflamed, so those hormone signals are blunted. The pancreas itself is structurally fine, but it doesn’t receive the message to start working.
Up to 80% of newly diagnosed celiac patients show some degree of impaired pancreatic function on testing. The good news is that this form of EPI is largely reversible. As the intestinal lining heals on a gluten-free diet, hormone signaling recovers and enzyme secretion normalizes. Some patients benefit from temporary enzyme replacement therapy during the healing period, and many can eventually stop taking it. When celiac patients don’t improve on a strict gluten-free diet, unrecognized EPI is one of the first things to investigate.
Shwachman-Diamond Syndrome
Shwachman-Diamond syndrome is a rare inherited condition and the second most common genetic cause of EPI after cystic fibrosis. It’s caused by mutations in one of several genes (most commonly SBDS) that are involved in building ribosomes, the cellular machinery responsible for making proteins. The pancreas is affected early: signs of pancreatic dysfunction typically appear in the first year of life, often within the first six months. Children present with fatty stools, poor growth, and failure to thrive.
Unlike cystic fibrosis, some children with Shwachman-Diamond syndrome experience partial improvement in pancreatic function over time, though the bone marrow problems that come with the condition (low blood counts and an increased risk of leukemia) remain a lifelong concern.
How EPI Is Detected
The most widely used screening test measures a digestive enzyme called elastase in a stool sample. Elastase is produced exclusively by the pancreas and passes through the gut without being broken down, so its concentration in stool reflects how much the pancreas is actually producing. A level above 200 micrograms per gram of stool is normal. Between 100 and 200 indicates mild insufficiency. Below 100 points to severe insufficiency and a strong likelihood that enzyme replacement will help with symptoms.
The test has limitations. It can miss mild cases, and watery stool can dilute the sample and produce a falsely low reading. But for most people with significant EPI, it provides a clear and practical answer, and it only requires a single stool sample with no special preparation.